Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and often confers a good prognosis. Though surgery is the gold standard of treatment, unresectable or metastatic disease can necessitate systemic therapy. Of systemic agents, there is increasing interest in the use of immunotherapies and targeted therapy. Further study into the driver mutations in cSCC has identified opportunities for targeted therapy. In this review, we discuss both current and investigational immune and molecular targets of therapy for cSCC.

No abstract

Acute generalized exanthematous pustulosis (AGEP) is a rare, potentially lethal, cutaneous reaction most commonly precipitated by drugs. Removal of the offending drug or treatment of the underlying infection usually results in recovery, though corticosteroids are often used to bolster treatment. We report a case of hydroxychloroquine-induced AGEP in an adult female. Though removal of hydroxychloroquine (HCQ) did largely resolve her rash, she continued to require corticosteroids over 200 days after she first began taking HCQ.